About Glycotope
Glycotope is a Healthcare company based in Berlin (Germany) founded in 2001, and was acquired by Celonic in November 2017. Developer of Glyco-optimized antibodies and provider of contract research and manufacturing services. Glycotope has raised $166.21 million across 4 funding rounds from investors including Octapharma, ELSA and Celonic. The company has 116 employees. Its chief executive, as recorded, is Steffen Goletz. Glycotope offers products and services including CXCR4 Compound and PentixaTher. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Antibody. Its legal entity is Glycotope GmbH.
Company details
Glycotope develops therapeutics based on glycosylation structures, as well as antibodies against glyco-epitopes on cancer cells. Its leading candidate GlycoBody PankoMab-GE is a proprietary antibody that is currently in phase 2 of clinical trials for ovarian and lung cancer. Other antibodies include EGFR antibody CetuGEX, glyco-optimized cetuximab for head and neck cancer; TrasGEXm, a Glycotopes HER2 antibody for gastric cancer; and others. It also offers a wide range of analytical, manufacturing and other research services. It also offers immune function assay kits based on flow cytometry procedures.
- Headquarters Berlin, Germany
- Employees 116
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website glycotope.com
- Social LinkedIn
- Acquired by Celonic (Nov 2017)
- Legal Name Glycotope Gmbh
- Annual Revenue$17.78 M (USD)31as on Dec 31, 2015
- Net Profit-$12.06 M (USD)74as on Dec 31, 2015
- Total Equity Funding$166.21M (USD)
in 4 rounds
- Latest Funding Round$90.03M (USD), Series B
Oct 2015
- InvestorsOctapharma
& 2 more
- Employee Count116
- Acquired byCelonic
(Nov 2017)
Products & Services of Glycotope
Glycotope offers a comprehensive portfolio of products and services, including CXCR4 Compound and PentixaTher.
Extensively studied for patient administration in cancer research.
Yttrium-90-based therapy for treating solid tumors.
Funding Insights of Glycotope
Glycotope has successfully raised a total of $166.21M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $90.03 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $166.21M
- Total Rounds 4
- Last Round Series B — $90.03M
- Investors Count 2
All 4 funding rounds of Glycotope with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $90.03M | Series B | – | Octapharma | – |
| Mar 2014 | $76.18M | Series A | – | Eckert Life Science Accelerator | – |
| Jun 2007 | Series A | – | – | – | |
| Jun 2001 | Seed | – | Eckert Life Science Accelerator | – |
3 investors in total: 3 institutional.
Investors in Glycotope
Glycotope has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Octapharma, ELSA and Celonic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A Berlin-based life science incubator and venture capital provider. | 1992 | elsalifescience.com | Berlin, Germany | |
High-quality human proteins are developed and produced by Octapharma. | octapharma.com | |||
Provides contract development and manufacturing services for biologics to biotech companies. | 1998 | celonic.com | Basel, Switzerland |
Investor details for Glycotope
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Glycotope
5 people are tracked at Glycotope (5 in leadership); the tracked headcount is 116.
| Name | Role | Group |
|---|---|---|
Steffen Goletz | CEO | Leadership |
Zurlo Alfredo | Managing Director | Leadership |
Henner Kollenberg | CEO | Leadership |
Franz Peter Bracht | Managing Director | Leadership |
Hans Builder | Leadership |
Complete people profiles for Glycotope
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Glycotope
4 dated milestones of Glycotope across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Glycotope is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $90.0M.
- Exit Acquired by Celonic.
Web traffic of Glycotope
Websites that share an audience with Glycotope (glycotope.com).
Websites whose visitors overlap most with Glycotope. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
jkbio.com | jkbio.com | 100% | – | ||
fudabiochem.com | fudabiochem.com | 100% | – | ||
candorly.com | candorly.com | 100% | – | ||
| ludger.com | 100% | 4.9K | #4,022,599 | View details | |
| nzp.co.nz | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Glycotope
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glycotope
Complete news archive for Glycotope
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycotope
Glycotope was founded in 2001.
Glycotope is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Steffen Goletz is the CEO of Glycotope, as recorded in our data.
Glycotope is a funded company, having raised a total of $166.21M across 4 funding rounds to date.
Glycotope has 116 employees.
Annual revenue of Glycotope is $17.78M as on Dec 31, 2015.
Glycotope develops therapeutics based on glycosylation structures, as well as antibodies against glyco-epitopes on cancer cells. Its leading candidate GlycoBody PankoMab-GE is a proprietary antibody that is currently in phase 2 of clinical trials for ovarian and lung cancer. Other antibodies include EGFR antibody CetuGEX, glyco-optimized cetuximab for head and neck cancer; TrasGEXm, a Glycotopes HER2 antibody for gastric cancer; and others. It also offers a wide range of analytical, manufacturing and other research services. It also offers immune function assay kits based on flow cytometry procedures.
Glycotope offers CXCR4 Compound and PentixaTher.
Glycotope has 3 investors. Key investors include Octapharma, ELSA, and Celonic.
Glycotope operates through Glycotope Gmbh.
Yes. Glycotope was acquired by Celonic in November 2017.